Skip to content
NeuroTechGuide

Spiro Medical implants its nerve stimulator in a first patient with severe asthma

The PULSAR feasibility study, running under an FDA investigational device exemption, plans to enroll up to 30 adults whose asthma stays uncontrolled despite medication.

In briefClinical trialsNeuromodulation

Spiro Medical said on October 12 that the first patient has been treated in PULSAR, a feasibility study of its implanted neuromodulation system for severe, uncontrolled asthma. The patient was enrolled through the University of Florida’s neurosurgery department and implanted in Gainesville. The study runs under an FDA investigational device exemption and plans to enroll up to 30 adults at several US centers, led by Michael Wechsler of National Jewish Health.

The device stimulates spinal nerves to act on the autonomic pathways that affect airway narrowing and inflammation. It is meant to be used alongside drugs, for people whose asthma is not controlled by inhalers or biologics. The announcement gives no endpoints or results, and the system is investigational. Spiro raised $67 million in January to fund this work.

Learn more: Clinical trial pathway

Share:XLinkedInBlueskyEmail

More news